Atlas Trials

Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Lymphomas

Clinical trial NCT03119467 · TERMINATED

Trial details

NCT number
NCT03119467
Sponsor
Rhizen Pharmaceuticals SA
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Lymphoma
Start date
2017-05-11
Primary completion
2019-11-29
Enrollment
21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.